Kaleido Biosciences (KLDO) Stock Price, News & Analysis

Company Overview

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 8,998 shs
• Market Capitalization: $6.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KLDO Stock Analysis - Frequently Asked Questions

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) announced its earnings results on Monday, November, 1st. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.54). The firm earned $0.10 million during the quarter, compared to analyst estimates of $0.25 million.

When did Kaleido Biosciences IPO?

Kaleido Biosciences (KLDO) raised $101 million in an initial public offering on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kaleido Biosciences investors own include Editas Medicine (EDIT), Enovix (ENVX), COMPASS Pathways (CMPS), Rambus (RMBS), Luminar Technologies (LAZR), Precision BioSciences (DTIL) and Globant (GLOB).

Company Calendar

• Last Earnings: 11/01/2021
• Today: 7/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Computer Software
• Current Symbol: NASDAQ:KLDO
• CIK: 1751299
• Web: www.kaleido.com
• Phone: (617) 674-9000
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.10 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 42,623,000
• Free Float: 38,787,000
• Market Cap: $6.39 million
• Optionable: Not Optionable
• Beta: -0.06